Drug intelligence / Profile preview

3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid

Development stage: Preclinical
Modality: Small Molecules

Overview

3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid is a synthetic small molecule belonging to the class of delta amino acids and derivatives. It is primarily used as a discovery or investigative agent in research settings. The compound acts as an inhibitor of delta-aminolevulinic acid dehydratase (ALAD), an enzyme involved in the early steps of heme biosynthesis and tetrapyrrole metabolism. By inhibiting ALAD, it can disrupt porphyrin and chlorophyll metabolic pathways, which are essential for cellular processes such as heme production[1][5][7]. There are no approved therapeutic indications; its use is limited to experimental studies.

Other names: 3-(2-AMINOETHYL)-4-(AMINOMETHYL)HEPTANEDIOIC ACID

Targets

ALAD (5-aminolevulinic acid dehydratase)

Beyond the preview

Go deeper on 3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-(2-aminoethyl)-4-(aminomethyl)heptanedioic acid.

Explore the full profile